Docetaxel trials for HER2-positive Breast Cancer

All Docetaxel trials · All HER2-positive Breast Cancer trials

Phase breakdown

Recruiting trials studying Docetaxel for HER2-positive Breast Cancer

• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
  NCT07518173 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
  NCT06891833 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 30 locations
• Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
  NCT06348134 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 4 locations
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
  NCT06441890 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
  NCT07377643 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Docetaxel for HER2-positive Breast Cancer?

6 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.